Johnsson F, Hatlebakk J G, Klintenberg A C, Román J
Dept. of Surgery, Lund University Hospital, Lund, Sweden.
Scand J Gastroenterol. 2003 Apr;38(4):347-53. doi: 10.1080/00365520310002157.
To assess symptom relief in patients with heartburn following treatment with esomeprazole 40 mg daily.
Patients with heartburn (for > or = 6 months) were assessed in this double-blind, multicenter study. After a 3-day single-blind placebo run-in, 440 patients were randomized to esomeprazole 40 mg o.d., esomeprazole 20 mg b.i.d. or placebo for 14 days. Heartburn symptoms were recorded daily; as insufficient patients had data available from days 13 and 14, analyses included data up to day 12. Gastroesophageal reflux disease (GERD) was diagnosed by upper GI endoscopy and 24-h pH-monitoring. The primary end-point was total heartburn relief defined as no heartburn symptoms during the preceding 24-h period.
240 patients had erosive esophagitis (EO) and 114 patients had GERD defined by pH-monitoring. Proportions of patients with total heartburn relief increased during the first days of treatment and stabilized after Day 4. Total heartburn relief occurred in 67%-73%, 62%-70%, and 21%-32% of patients in the esomeprazole 40 mg o.d., esomeprazole 20 mg b.i.d., and placebo groups, respectively, between days 6 and 12. Proportions of patients with total heartburn relief were higher in patients with EO (71%-80% of patients from Day 4 onwards) compared to those without EO (52%-67% of patients from Day 4 onwards). Figures for patients diagnosed by pH-monitoring were 65%-73% of those with a positive diagnosis and 51%-58% with a negative diagnosis.
Esomeprazole 40 mg o.d. treatment produces total heartburn relief in a high proportion of patients with GERD. Once-daily esomeprazole 40 mg dosing is recommended as no advantage was gained by splitting the dose.
评估每日服用40毫克埃索美拉唑治疗烧心患者后的症状缓解情况。
在这项双盲、多中心研究中评估烧心(持续≥6个月)患者。经过为期3天的单盲安慰剂导入期后,440例患者被随机分为每日服用40毫克埃索美拉唑、每日服用2次20毫克埃索美拉唑或服用安慰剂,疗程为14天。每天记录烧心症状;由于从第13天和第14天获得数据的患者不足,分析纳入了截至第12天的数据。通过上消化道内镜检查和24小时pH监测诊断胃食管反流病(GERD)。主要终点是完全烧心缓解,定义为在前24小时内无烧心症状。
240例患者患有糜烂性食管炎(EO),114例患者通过pH监测诊断为GERD。在治疗的头几天,完全烧心缓解的患者比例增加,并在第4天后稳定下来。在第6天至第12天期间,每日服用40毫克埃索美拉唑组、每日服用2次20毫克埃索美拉唑组和安慰剂组中完全烧心缓解的患者比例分别为67%-73%、62%-70%和21%-32%。与无EO的患者(从第4天起为52%-67%)相比,EO患者中完全烧心缓解的比例更高(从第4天起为71%-80%)。通过pH监测诊断的患者中,诊断阳性者的比例为65%-73%,诊断阴性者的比例为51%-58%。
每日服用40毫克埃索美拉唑治疗可使高比例的GERD患者完全缓解烧心症状。建议每日一次服用40毫克埃索美拉唑,因为分剂量服用并无优势。